Related Experiment Video
Updated: Mar 10, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.3K
Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials
Francisco Beca1,2, Andrew H Beck1,2
1Department of Pathology and Cancer Research Institute, Beth Israel Deaconess Cancer Center, Boston, Massachusetts, United States of America.
Plos Medicine
|December 7, 2016
Summary
This study examines somatic mutations in inflammatory breast cancer patients during a Phase II clinical trial. The findings offer insights into the genetic landscape of this aggressive cancer subtype.
Area of Science:
- Oncology
- Genetics
- Clinical Trials
Background:
- Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer with poor prognosis.
- Understanding the genetic underpinnings of IBC is crucial for developing targeted therapies.
Purpose of the Study:
- To analyze somatic mutations in patients with inflammatory breast cancer.
- To correlate genetic alterations with treatment response in a Phase II clinical trial.
Main Methods:
- Whole-exome sequencing or targeted gene sequencing of tumor samples.
- Analysis of clinical data from patients treated in a Phase II trial.
Main Results:
- Identification of recurrent somatic mutations in key cancer-related genes.
- Potential associations between specific mutations and clinical outcomes were explored.
Conclusions:
- Somatic mutations play a significant role in the pathogenesis of inflammatory breast cancer.
- These genetic insights may inform future therapeutic strategies for IBC.
